These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1006 related articles for article (PubMed ID: 31714156)

  • 21. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
    Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
    Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of ageing on natural killer cell function and potential consequences for health in older adults.
    Hazeldine J; Lord JM
    Ageing Res Rev; 2013 Sep; 12(4):1069-78. PubMed ID: 23660515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
    Draghiciu O; Lubbers J; Nijman HW; Daemen T
    Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging role of natural products in cancer immunotherapy.
    Dong S; Guo X; Han F; He Z; Wang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
    Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
    J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells.
    Jewett A; Wang MY; Teruel A; Poupak Z; Bostanian Z; Park NH
    Hum Immunol; 2003 May; 64(5):505-20. PubMed ID: 12691701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
    Xu LJ; Ma Q; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
    Mol Med Rep; 2018 Jun; 17(6):8111-8120. PubMed ID: 29693186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.
    Michaud HA; Eliaou JF; Lafont V; Bonnefoy N; Gros L
    Oncoimmunology; 2014 Oct; 3(9):e955684. PubMed ID: 25941618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
    J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MICA/IL-12: A novel bifunctional protein for killer cell activation.
    Tietje A; Yang X; Yu X; Wei Y
    Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.
    Sarhan D; Cichocki F; Zhang B; Yingst A; Spellman SR; Cooley S; Verneris MR; Blazar BR; Miller JS
    Cancer Res; 2016 Oct; 76(19):5696-5706. PubMed ID: 27503932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells.
    Yusa S; Catina TL; Campbell KS
    J Immunol; 2002 May; 168(10):5047-57. PubMed ID: 11994457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrophages are critical effectors of antibody therapies for cancer.
    Weiskopf K; Weissman IL
    MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.